Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium-68 Citrate PET in DLBCL
NCT02776891Phase 2Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Jun 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gallium citrate in diffuse large B-cell lymphoma (DLBCL), B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (GZL), sponsored by University of California, San Francisco. Planned start Jun 2016; status: withdrawn.
02
Drugs
gallium citrate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (GZL)
Beyond the preview
Go deeper on NCT02776891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776891.